In a patient with hyperthyroidism and elevated alkaline phosphatase and alanine aminotransferase (ALT), is it appropriate to initiate methimazole?

Can You Prescribe Methimazole in a Patient with Hyperthyroidism and Elevated Alkaline Phosphatase and ALT?

Yes, you can prescribe methimazole in this patient, but you must first determine the degree of liver enzyme elevation and proceed with caution based on specific thresholds.

Critical Decision Points

The key determination is whether the transaminase elevation exceeds 5 times the upper limit of normal (ULN), as this represents an absolute contraindication to initiating antithyroid drug therapy 1.

Baseline Assessment Required

Before initiating methimazole, obtain:

• Complete blood count with differential
• Liver profile including bilirubin, ALT, AST, and alkaline phosphatase 1

If baseline ALT or AST >5× ULN: Do NOT start methimazole - consider radioactive iodine or surgery instead 1.

Understanding the Liver Enzyme Elevation

Hyperthyroidism itself frequently causes abnormal liver function tests. In fact, 32.5% of patients with newly diagnosed overt hyperthyroidism have abnormal LFTs at baseline 2. The elevated alkaline phosphatase and ALT in your patient may be:

1. Due to the hyperthyroidism itself - thyrotoxicosis commonly causes mild-to-moderate hepatocellular injury
2. Unrelated to thyroid disease - requires clinical judgment

Importantly, studies show that in most patients with baseline abnormal LFTs, methimazole treatment actually results in normalization of serum ALT and AST as the hyperthyroidism is controlled 2.

When Methimazole Can Be Safely Started

If transaminases are <5× ULN, methimazole remains the preferred antithyroid drug and should be initiated 1. The 2011 ATA/AACE guidelines explicitly state: "Methimazole should be used in virtually every patient who chooses antithyroid drug therapy for Graves' disease" 1.

Dosing Strategy

• Start with 10-20 mg daily for moderate-to-severe hyperthyroidism
• Titrate to maintenance dose of 5-10 mg daily once euthyroid 1

Monitoring Protocol After Initiation

Critical monitoring thresholds 1:

1. Check free T4 at 4 weeks, then every 4-8 weeks until euthyroid
2. Monitor liver enzymes if patient develops symptoms (jaundice, dark urine, light stools, abdominal pain, nausea, fatigue)
3. Stop methimazole immediately if transaminases reach 2-3× ULN and fail to improve within 1 week of repeat testing 1

Patient Education Requirements

You must inform the patient (verbally and in writing) to stop methimazole immediately and call you if they develop 1:

• Jaundice
• Dark urine or light-colored stools
• Abdominal pain or bloating
• Nausea or fatigue
• Fever or pharyngitis (agranulocytosis warning)

Important Nuances About Methimazole Hepatotoxicity

Methimazole hepatotoxicity is typically cholestatic, not hepatocellular, and is generally less severe than PTU-induced liver injury 1. Recent evidence shows:

• Methimazole can be safely administered in hyperthyroid patients with abnormal baseline LFTs 2
• Low-dose methimazole was safe and effective even in patients with severe hepatic dysfunction from Graves' disease 3
• PTU causes fulminant hepatic necrosis and has resulted in 32 cases of serious liver injury (including 10 pediatric cases), with some requiring liver transplantation 1

Common Pitfall to Avoid

Do not reflexively avoid methimazole just because liver enzymes are elevated. The elevation may be from the hyperthyroidism itself, which will improve with treatment. The critical error would be switching to PTU in this scenario, as PTU has significantly higher hepatotoxicity risk and can cause fulminant hepatic failure 1, 4.

If Methimazole Cannot Be Used

Only if transaminases are >5× ULN or if severe hepatotoxicity develops during treatment should you consider:

1. Radioactive iodine therapy (preferred)
2. Thyroidectomy (if radioactive iodine contraindicated)
3. NOT propylthiouracil - except in very specific circumstances (first trimester pregnancy, thyroid storm, or minor methimazole reaction with refusal of definitive therapy) 1

Exception for Severe PTU-Induced Hepatotoxicity

The guidelines note: "Except in cases of severe PTU-induced hepatotoxicity, methimazole can be used to control thyrotoxicosis without ill effect" even after liver injury from PTU 1. This underscores methimazole's relative safety compared to PTU.